S
Samantha Dale Strasser
Researcher at Beth Israel Deaconess Medical Center
Publications - Â 6
Citations - Â 245
Samantha Dale Strasser is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: KRAS & Phosphorylation. The author has an hindex of 5, co-authored 5 publications receiving 153 citations. Previous affiliations of Samantha Dale Strasser include Massachusetts Institute of Technology.
Papers
More filters
Journal ArticleDOI
Tissue-Specific Oncogenic Activity of KRASA146T
Emily J. Poulin,Emily J. Poulin,Asim K. Bera,Jia Lu,Yi Jang Lin,Yi Jang Lin,Samantha Dale Strasser,Samantha Dale Strasser,Joao A. Paulo,Tannie Q. Huang,Carolina Morales,Wei Yan,Joshua Cook,Joshua Cook,Jonathan A. Nowak,Douglas K. Brubaker,Douglas K. Brubaker,Douglas K. Brubaker,Brian A. Joughin,Christian W. Johnson,Christian W. Johnson,Rebecca A. Destefanis,Rebecca A. Destefanis,Phaedra C. Ghazi,Phaedra C. Ghazi,Sudershan R. Gondi,Thomas E. Wales,Roxana E. Iacob,Lana Bogdanova,Jessica J. Gierut,Jessica J. Gierut,Yina Li,Yina Li,John R. Engen,Pedro A. Perez-Mancera,Benjamin S. Braun,Steven P. Gygi,Douglas A. Lauffenburger,Kenneth D. Westover,Kevin M. Haigis,Kevin M. Haigis +40 more
TL;DR: It is demonstrated that the selection for specific KRAS mutants in human cancers from different tissues is due to their distinct signaling properties, demonstrating that context-dependent variations in signaling downstream of differentKRAS mutants drive the KRAS mutational pattern seen in cancer.
Journal ArticleDOI
Systems biology of neurodegenerative diseases
TL;DR: It is envisioned that the integration of computational approaches with multiple omic analyses of human tissues, and mouse and in vitro models, will enable the discovery of new therapeutic strategies for these devastating diseases.
Journal ArticleDOI
Proteogenomic Network Analysis of Context-Specific KRAS Signaling in Mouse-to-Human Cross-Species Translation
Douglas K. Brubaker,Douglas K. Brubaker,Douglas K. Brubaker,Joao A. Paulo,Shikha S. Sheth,Shikha S. Sheth,Emily J. Poulin,Emily J. Poulin,Olesja Popow,Olesja Popow,Brian A. Joughin,Samantha Dale Strasser,Alina Starchenko,Alina Starchenko,Alina Starchenko,Steven P. Gygi,Douglas A. Lauffenburger,Kevin M. Haigis,Kevin M. Haigis +18 more
TL;DR: The approach to statistically humanize the mouse networks with data from human cancer and identified genes within the humanized CRC and PDAC networks synthetically lethal with mutant KRAS to demonstrate the context-dependent plasticity of oncogenic signaling.
Journal ArticleDOI
Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis
Jesse Lyons,Jesse Lyons,Douglas K. Brubaker,Douglas K. Brubaker,Phaedra C. Ghazi,Katherine R. Baldwin,Katherine R. Baldwin,Amanda L. Edwards,Myriam Boukhali,Samantha Dale Strasser,Samantha Dale Strasser,Lucia Suarez-Lopez,Lucia Suarez-Lopez,Yi-Jang Lin,Vijay Yajnik,Joseph L. Kissil,Wilhelm Haas,Douglas A. Lauffenburger,Kevin M. Haigis,Kevin M. Haigis +19 more
TL;DR: A multiomics analysis that integrated RNA microarray, total protein mass spectrometry, and phosphoproteomics analyses of tissues isolated from a mouse model of colitis identified Pak as a potential therapeutic target in IBD.
Journal ArticleDOI
Substrate-based kinase activity inference identifies MK2 as driver of colitis
Samantha Dale Strasser,Phaedra C Ghazi,Phaedra C Ghazi,Alina Starchenko,Alina Starchenko,Alina Starchenko,Myriam Boukhali,Amanda L. Edwards,Lucia Suarez-Lopez,Lucia Suarez-Lopez,Lucia Suarez-Lopez,Jesse Lyons,Jesse Lyons,Jesse Lyons,Paul S. Changelian,Joseph B Monahan,Jon Jacobsen,Douglas K. Brubaker,Douglas K. Brubaker,Douglas K. Brubaker,Brian A. Joughin,Michael B. Yaffe,Wilhelm Haas,Douglas A. Lauffenburger,Kevin M. Haigis,Kevin M. Haigis +25 more
TL;DR: These studies establish MK2 as a therapeutic target in IBD and identify ATI450 as a potential therapy for the disease with treatment of mice with active colitis with ATI450, an orally bioavailable small molecule inhibitor of the MK2 pathway.